发明授权
US6156752A Optically active 1,4-dihydropyridine compounds as bradykinin antagonists
失效
光活性1,4-二氢吡啶化合物作为缓激肽拮抗剂
- 专利标题: Optically active 1,4-dihydropyridine compounds as bradykinin antagonists
- 专利标题(中): 光活性1,4-二氢吡啶化合物作为缓激肽拮抗剂
-
申请号: US133580申请日: 1998-08-13
-
公开(公告)号: US6156752A公开(公告)日: 2000-12-05
- 发明人: Takafumi Ikeda , Mitsuhiro Kawamura , Yu-Ting Ge
- 申请人: Takafumi Ikeda , Mitsuhiro Kawamura , Yu-Ting Ge
- 申请人地址: NY New York
- 专利权人: Pfizer Inc
- 当前专利权人: Pfizer Inc
- 当前专利权人地址: NY New York
- 优先权: WOXPCT/IB97/01000 19970818
- 主分类号: C07D487/04
- IPC分类号: C07D487/04 ; A61K31/4427 ; A61K31/455 ; A61K31/55 ; A61P1/00 ; A61P3/08 ; A61P9/00 ; A61P11/00 ; A61P13/02 ; A61P15/00 ; A61P17/00 ; A61P25/04 ; A61P25/28 ; A61P29/00 ; A61P31/04 ; A61P31/12 ; A61P35/00 ; A61P37/08 ; A61P43/00 ; C07D211/90 ; C07D401/06 ; C07D401/12 ; C07D401/14 ; C07D451/02 ; C07D451/04 ; C07D453/02 ; C07D453/06 ; A61K31/497
摘要:
This invention provides a compound of the formula (I): ##STR1## and its pharmaceutically acceptable salts, wherein A.sup.1 and A.sup.2 are each halo; R.sup.1 and R.sup.2 are independently C.sub.1-4 alkyl; R.sup.3 is substituted or unsubstituted, phenyl or naphthyl; Y is heterocyclic group selected from C.sub.5-10 azacycloalkyl, C.sub.6-10 diazacycloalkyl, C.sub.7-10 azabicycloalkyl and the like; and R.sup.4 is selected from (a) substituted or unsubstituted C.sub.1-8 alkyll; (b) substituted or unsubstituted amino; (c) substituted or unsubstituted C.sub.2-6 alkanoyl; (d) substituted or unsubstituted C.sub.3-8 cycloalkyl or C.sub.7-14 bicycloalkyl; (e) substituted or unsubstituted C.sub.5-10 azacycloalkyl or C.sub.6-10 diazacycloalkyl, and (f) substituted or unsubstituted C.sub.7-14 mono- or di-azabicycloalkyl. These compounds are useful for the treatment of medical conditions caused by bradykinin such as inflammation, cardiovascular disease, pain, etc. This invention also provides a pharmaceutical composition comprising the above compound, and intermediates of the above compounds.
公开/授权文献
- US4282648A CMOS process 公开/授权日:1981-08-11